Skip to Content
Søk Menu

The Missing Link of Light Chain Smoldering Multiple Myeloma

The iStopMM study provides valuable new data on precursors of multiple myeloma, proposing a novel definition for light chain smoldering myeloma and identifying key risk factors for MCAS.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Relaterat innehåll

Muhammad Kashif

Novel Risk Stratification Method for Bone Disease in Multiple Myeloma Patients Minimizes Radiation Exposure and Lowers Economic Burden

/ Muhammad Kashif
AIASH24Myelom Play the Video 03:57
Meletios-Athanasios Dimopoulos

Daratumumab Monotherapy Shows Clinical Benefit for Early Intervention for Patients with High-Risk Smoldering Multiple Myeloma

/ Meletios A. Dimopoulos
ASH24Myelom Play the Video 03:38
Frida Bugge Askeland

Positive Outcome of Steroid Replacement in Transplant-Ineligible Myeloma

/ Frida Bugge Askeland
ASH24Myelom Play the Video 03:10
Fredrik Schjesvold

ASH 2024 Highlights: Early Smouldering Myeloma Treatment and Breakthrough Therapies in Multiple Myeloma Take Center Stage

/ Fredrik Schjesvold
ASH24Myelom Play the Video 02:57
Alex Lesokhin

Elranatamab Demonstrates Sustained Efficacy with Reduced Dosing Frequency in Refractory Multiple Myeloma

/ Alexander Lesokhin
ASH24Myelom Play the Video 4:45

The Aquila Study Strongly Supports the Benefit of Early Intervention with Daratumumab Monotherapy in Patients with High-Risk Smoldering Multiple Myeloma

/ Jan Andreasen
ASH24Myelom
Fredrik Schjesvold

The Trispecific Antibody SAR’257 Discontinued After Phase 1 Findings

/ Fredrik Schjesvold
ASH24Myelom Play the Video 03:29

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelom

Using PRO Data to Assess Treatment Readiness in Multiple Myeloma

/ Tine Rosenberg / Thomas Lund / Jannie Kirkegaard
Myelom
Back to top